Helius Medical Technologies Inc Class A Overview
Industry: Medical Devices
Sector: Healthcare
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania. Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical devi Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Helius Medical Technologies Inc Class A into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $3.6M (reported). Operating income was $0.2M. Net loss was -$99.8M.
What changed
- Revenue reported to $3.6M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Earnings call transcript: Solana Company Q2 2026 revenue misses forecast
Headline from Investing.com: Earnings call transcript: Solana Company Q2 2026 revenue misses forecast.
Solstice splits a Nasdaq stock dividend into two risk tokens on Solana
Headline from Yahoo Finance Singapore: Solstice splits a Nasdaq stock dividend into two risk tokens on Solana.
Solstice splits a Nasdaq stock dividend into two risk tokens on Solana
Headline from Yahoo Finance: Solstice splits a Nasdaq stock dividend into two risk tokens on Solana.
Solana Company Q2 Loss Hits $30.3 Million as SOL Treasury Suffers
Headline from Yahoo Finance: Solana Company Q2 Loss Hits $30.3 Million as SOL Treasury Suffers.
Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates
Headline from Yahoo Finance: Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates.
Bitcoin, Ethereum, XRP or Solana: Which ETF will grow the most in 2026?
Headline from Yahoo Finance: Bitcoin, Ethereum, XRP or Solana: Which ETF will grow the most in 2026?
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.